Concepedia

Susan Laffan

SL

Statistics

Publications

9

Citations

250

H-Index

9

Active since

2006

Affiliations

GlaxoSmithKline (United States)(Current)

GlaxoSmithKline (United Kingdom)

Research Triangle Park Foundation

Covance (United States)

Charles River Laboratories (United States)

Susan Laffan is an author at GlaxoSmithKline (United States) specializing in toxicology, developmental toxicology, and pharmacology.

ORCID

Publications per year

2006–2020

9

Publications

9

Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo

Tacey White, Paul Bushdid, S. Ritter et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 2006 · 78 citations

, , +15

Imaging MS in Toxicology: An Investigation of Juvenile Rat Nephrotoxicity Associated with Dabrafenib Administration

M. Reid Groseclose, Susan Laffan, Kendall S. Frazier et al. · Journal of the American Society for Mass Spectrometry · 2015 · 54 citations · Full text

, , +14

Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects

Peter T. Theunissen, Sonia Beken, Bruce Beyer et al. · Critical Reviews in Toxicology · 2016 · 30 citations · Full text

, , +16

Absence of developmental and reproductive toxicity in animals exposed to dolutegravir

Dinesh Stanislaus, Lorraine M. Posobiec, Susan Laffan et al. · Birth Defects Research · 2019 · 18 citations

, , +17

Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates

Susan Laffan, Andrew S. Thomson, Shing Mai et al. · PLoS ONE · 2020 · 17 citations · Full text

, , +17

1–5 of 9